This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Roche to Absorb Seragon Pharmaceuticals

NEW YORK (The Deal) -- European drugmakers continued to look across the Atlantic on Wednesday to expand their portfolios with Switzerland's Roche Holding agreeing to buy recently created San Diego biotech Seragon Pharmaceuticals for up to $1.73 billion and France's Nicox arranging to pay as much as $120 million for Boston's Aciex Therapeutics Inc.

Roche, through its Genentech division, would pay $725 million upfront for Seragon and as much as $1 billion in milestone payments should the target's experimental breast cancer treatment prove viable.

Seragon was spun out of Aragon Pharmaceuticals Inc. after Johnson & Johnson agreed to buy Aragon last fall for as much as $1 billion. It's developing a breast cancer treatment that could target rogue cells that alter the cells that absorb estrogen.

Roche says 60% of breast cancers are estrogen-related and are often fought by halting the hormone's uptake. Unfortunately, when treatment ends -- and hormone absorption resumes -- cancer often returns or worsens.

Seragon's treatment could help, but it's at the first of three trial phases. It could be five years or more until it's ready for the market.

Seragon was funded by Aragon's backers, including Column Group, OrbiMed Advisors, Aisling Capital, TopSpin and venBio.

Meanwhile, in France, Nicox agreed to pay $65 million in new shares for Aciex Therapeutics as well as the rights to an additional $55 million in shares should certain conditions be met.

Aciex is developing a number of treatments for such eye maladies as conjunctivitis, dryness and post-surgical swelling.

"The combination with Aciex would enable Nicox to expand its therapeutic pipeline to target major segments of the ophthalmic sector, including the $816 million U.S. allergic conjunctivitis market," Nicox CEO Michele Garufi said in a statement.

Aciex was founded in 2007 and is backed by Akorn Inc., Bay City Capital LLC, HealthCare Ventures LLC, New Enterprise Associates Inc. and Ora Investment Group.

In the Seragon deal, the target took counsel from Wilson Sonsini Goodrich & Rosati PC.

In the Nicox acquisition of Aciex, MTS Securities LLC acted as financial adviser to Nicox with Mintz Levin Cohn Ferris Glovsky and Popeo PC as well as Clifford Chance LLP providing counsel.

Aquilo Partners LP acted as financial adviser to Aciex and Wilmer Cutler Pickering Hale and Dorr LLP as legal adviser.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs